Leerink Partnrs Estimates Nkarta’s Q1 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) – Research analysts at Leerink Partnrs raised their Q1 2025 earnings estimates for shares of Nkarta in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will post earnings of ($0.46) per share for the quarter, up from their previous forecast of ($0.51). The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta’s Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.44) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.66) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at ($1.34) EPS.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.06.

Several other equities analysts have also recently commented on the stock. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Nkarta in a report on Thursday. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Nkarta in a research note on Thursday. Finally, Stifel Nicolaus cut their price target on Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Nkarta currently has an average rating of “Buy” and a consensus price target of $14.86.

Nkarta Stock Performance

Shares of NKTX opened at $2.00 on Monday. The company has a market capitalization of $141.92 million, a PE ratio of -1.06 and a beta of 0.90. The company’s 50 day moving average price is $1.99 and its 200 day moving average price is $2.82. Nkarta has a 52 week low of $1.31 and a 52 week high of $11.84.

Institutional Investors Weigh In On Nkarta

Hedge funds have recently bought and sold shares of the company. Wasatch Advisors LP lifted its position in shares of Nkarta by 31.7% during the 3rd quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock worth $8,293,000 after purchasing an additional 442,125 shares during the last quarter. Geode Capital Management LLC increased its position in Nkarta by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock worth $5,294,000 after buying an additional 33,927 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Nkarta by 252.1% during the third quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company’s stock worth $4,806,000 after buying an additional 761,349 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of Nkarta in the third quarter valued at approximately $151,000. Finally, FMR LLC grew its stake in shares of Nkarta by 97.1% in the third quarter. FMR LLC now owns 133,149 shares of the company’s stock worth $602,000 after acquiring an additional 65,600 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors.

Insider Activity at Nkarta

In related news, CEO Paul J. Hastings sold 17,378 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the transaction, the chief executive officer now directly owns 319,859 shares in the company, valued at approximately $703,689.80. This trade represents a 5.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 8.70% of the stock is owned by company insiders.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.